Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hyolim Bio is a South Korean biotechnology company specializing in the development of functional ingredients and therapeutic agents derived from natural sources. The company focuses on metabolic diseases, including obesity and diabetes, as well as liver health and dermatology. Hyolim Bio leverages its proprietary extraction and fermentation technologies to produce high-potency botanical extracts for the global nutraceutical and pharmaceutical markets. Their portfolio includes several patented ingredients that have demonstrated efficacy in regulating lipid metabolism and blood glucose levels. The company operates a dedicated research center and manufacturing facility to ensure the standardization and quality of its natural products. Hyolim Bio is actively expanding its pipeline into botanical drugs, moving beyond functional foods into clinical-stage therapeutic development.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hyolim Bio.